Transforming Healthcare for Everyone.
Positive Phase 2 clinical data with our lead candidate EDP1815 in psoriasis confirm that Evelo can harness SINTAX to treat systemic inflammatory diseases with an orally delivered medicine observed to have placebo-like safety and tolerability. EDP1815 – with its convenient oral delivery, together with affordable pricing – opens up the opportunity to treat hundreds of millions of people who are limited by current treatment options.
This is only the beginning.
Evelo’s small intestinal axis, SINTAX, platform has the potential to transform the global treatment of all stages of inflammatory disease.
Medicines for millions
Our product candidates have the potential to treat a range of inflammatory conditions at all stages of disease that impact hundreds of millions of people globally, including psoriasis, atopic dermatitis and other atopies, arthritic diseases, bowel disease, and neuroinflammatory diseases.
Effective, Safe and Well Tolerated, Oral and Convenient, and Affordable
Our product candidates are non-live single strains of microbes and extracellular vesicles that are room-temperature stable and can be taken orally. In clinical trials to-date, our lead product candidate was well-tolerated with safety data comparable to placebo.
SINTAX™: A NEWLY UNCOVERED AREA OF HUMAN BIOLOGY
We have proved we can harness the power of the small intestinal axis, SINTAX, to fight disease by returning the immune system to homeostasis.
Advancing our medicines for patients who need them
We are rapidly progressing our product candidates through research and clinical development in order to realize our vision of providing effective, safe and well-tolerated, oral and convenient, and affordable medicines to patients.
Our Culture
Life as an Evelonian
We have an ambitious, passionate, and dedicated team who are driven by the desire to have a major impact on global healthcare. We are committed to providing a phenomenal growth environment and opportunities for employees to help them realize their potential.
Stay in the Know
News
December 16, 2022
Evelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing Debt
November 15, 2022
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology
November 14, 2022
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights
Events
November 30, 2022
Understanding SINTAX Medicines and Their Potential to Treat Inflammatory Disease
Contact Us
We Want to Hear From You
Let’s start the conversation. For inquiries or requests for more information, reach out!
